Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease

Journal of Internal Medicine

Volumn 243, Issue 5, 1998, Pages 367-372

  Georgiou, S ^a   Monastirli, A ^a   Pasmatzi, E ^a   Gartaganis, S ^a   Goerz, G ^b   Tsambaos, D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aphthae; Behcet's disease; Interferon

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HUMAN; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031832992     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00159.x     Document Type: Article

References (35)

1. Adamantiades B. Sur en cas d'iritis a hypopyon recidivant. Ann Oculist 1931; 168: 271-8.
2. Behcet H, Über rezidivierende, aphthöse, durch em Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wschr 1937; 105: 1152-7.
3. Chajek T, Fainaru M. Behcet's disease: Report of 41 cases and review of the literature. Medicine 1975; 54: 179-96.
4. Arbesfeld SJ, Kurban AK. Behcet's disease. J Am Acad Dermatol 1988; 19: 767-79.
5. Namba K, Ueno T, Okita M. Behcet's disease and streptococcal infection. Jpn J Ophthalmol 1986; 30: 385-401.
6. Studd M, McCane DJ, Lehner T. Detection of HSV-1 DNA in patients with Behcet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991; 34: 39-43.
7. Mizuki N, Ohno S, Tanaka H, Sugimura K, Seki T, Mizuki N et al Association of HLA-B51 and lack of association of class II alleles with Behcet's disease. Tissue Antigens 1992; 40: 22-30.
8. Lee S, Bang D, Cho YH, Lee E-S, Sohn S. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behcet's disease. Arch Dermatol Res 1996; 288: 179-83.
9. Dührsen U, Kirch W. Therapie des Behcet-Syndroms. Dtsch med Wschr 1985; 110: 267-70.
10. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behcet's syndrome. Drugs 1991; 42: 796-804.
11. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet 1982; 2: 1356-60.
12. Berman B, Frankort HM. The human interferon system. Int J Dermatol 1982; 21: 12-8.
13. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986; 278: 335-6.
14. Stadler R, Bratzke B, Bauman I. Morbus Behcet und exogenes Interferon. Erfolgreicher Behandlungsversuch mit rekombiniertem α A-IFN. Hautarzt 1987; 38: 97-100.
15. Zouboulis Ch, Treudler R, Orfanos CE. Morbus Adamantiades-Behcet. Therapeutischer Einsatz von systemischem rekombinantem Interferon α-2a. Hautarzt 1993; 44: 440-5.
16. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behcet's disease. J Am Acad Dermatol 1994; 31: 617-19.
17. Hamuryudan V, Moral F, Yurdakul S, Mat S, Tüzün Y, Özyazgan Y et al. Systemic Interferon α2b treatment in Behcet's syndrome. J Rheumatol 1994; 21: 1098-100.
18. Azizlerli G, Sarica R, Köse A, Övül C, Kavala M, Kayaball M et al. Interferon alfa-2a in the treatment of Behcet's disease. Dermatology 1996; 192: 239-41.
19. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335: 1078-80.
20. Maddox RR, John JF, Brown LL, Smith CE. Effect of inline filtration on post-infusion phlebitis. Clin Pharm 1983; 2: 58-61.
21. Dumonde DC, Kasp-Grochowska E, Graham E, Sanders MD, Faure J-P, De Kozak Y et al. Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis. Lancet 1982; 2: 787-92.
22. Isaacs A, Lindenmann J, Virus interference. I. The Interferon. Roc R Soc Lond (Biol)1957; 147: 258-73.
23. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR et al., The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-83.
24. Sekar V, Atmar VJ, Joshi AR, Krim M, Kuehn G. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 1983; 114: 950-4.
25. Fleischmann WF Jr, Newton RC, Fleischmann CM, Colburn NH, Brysk MM. Discrimination between nonmalignant and malignant cells by combinations by IFNYγ and IFNαβ J Biol Response Mod 1984; 3: 397-405.
26. Wells V, Mallucci L. Expression of the 2-5A system during the cell cycle. Exp Cell Res 1985; 159: 27-36.
27. Niesel DW, Hess CB, Cho Y-J, Klimpel KD, Klimpel GR. Nutural and recombinant IFN inhibit tissue culture cell invasion by Salmonella and Shiyella. Infect Immun 1986; 52: 828-35.
28. Rhilip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity Induced by itself, γIFN and interleukin-1. Nature 1986; 323: 86-9.
29. Black CM, Remington JS, McCare RE. Toxoplasma. In: Byrne GI, Turco J, eds. Interferon and Nonviral Pathogens. New York, NY: Marcel Dekker Inc., 1988; 237-61.
30. Byrne GI, Interferons, immunity and Chlamydiae. In: Byrne GI. Turco J, eds. Interferon and Nonviral Pathogens. New York, NY: Marcel Dekker Inc., 1988; 53-72.
31. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990; 249: 796-8.
32. Kötter I, Dürk H, Saal JG, Eckstein A, Zierhut M, Fierlbeck G. Morbus Behcet. Epidemiologie, Verlauf, therapeutische Optionen. Dtsch med Wschr 1996; 121: 382-8.
33. Towler HMA, Lightman S. Visual prognosis in Behcet's disease. Ocul Immunol Inflamm 1993; 1: 249-54.
34. Durand JM, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-α2b in Behcet's disease. Arthr Rheumatism 1993; 36: 1025-6.
35. Feron EJ, Rothova A, van Hagen P, Baarsma Sattorp-Schulten MSA. Interferon-α2b for refractory ocular Behcet's disease. Lancet 1994; 343: 1428.